Product nameTerfenadine, K+ channel blocker. H1 antagonist.
DescriptionK+ channel blocker. H1 antagonist.
Biological descriptionK+ channel blocker (Kv11.1). Blocks ATP-sensitive K+ channels (IC50 = 1.2 μM). H1 receptor antagonist.
Storage instructionsStore at +4°C. The product can be stored for up to 12 months.
Solubility overviewSoluble in DMSO to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Our Abpromise guarantee covers the use of ab120270 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.|
ab2893 staining γH2A.X in MALME-3M cells treated with terfenadine (ab120270), by ICC/IF. Increase of γH2A.X nuclear expression correlates with increased concentration of terfenadine, as described in literature.
The cells were incubated at 37°C for 6 hours in media containing different concentrations of ab120270 (terfenadine) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab2893 (10 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
This product has been referenced in:
- Stork D et al. State dependent dissociation of HERG channel inhibitors. Br J Pharmacol 151:1368-76 (2007). Read more (PubMed: 17592502) »
- Crumb WJ Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 292:261-4 (2000). Read more (PubMed: 10604956) »
- Zünkler BJ et al. Mechanism of terfenadine block of ATP-sensitive K(+) channels. Br J Pharmacol 130:1571-4 (2000). Read more (PubMed: 10928959) »
- McTavish D et al. Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy. Drugs 39:552-74 (1990). Read more (PubMed: 1972050) »